拉米夫定预防鼻咽癌治疗相关性乙肝病毒再激活的疗效分析

目的探讨拉米夫定预防鼻咽癌治疗相关性乙型肝炎病毒再激活的疗效。方法收集2008年3月至2009年3月初治HBsAg（＋）鼻咽癌患者51例,将其分成两组：拉米夫定预防治疗组（A组,n=26例）和非预防治疗组（B组,n=25例）。A组患者在鼻咽癌放化疗前一周开始口服拉米夫定100mg／d,至放化疗结束后8w;B组未给予预防性口服拉米夫定。比较两组鼻咽癌治疗相关性肝炎发生率、HBV再激活率及放化疗中断率。结果鼻咽癌放化综合治疗期间,预防治疗组和非预防治疗组治疗相关性肝炎发生率、HBV再激活率及放化疗中断率分别为3．85％与32％、0％与28％、19．2％与56％,两组比较差异有显著性（P值〈0．05）。结论拉米夫定预防性治疗能够显著降低鼻咽癌治疗相关性肝炎的发生率、HBV再激活率及放化疗中断率。

Analysis of efficacy in Lamivudine for preventing nasophsryngeal carcinoma-treated-related hepatitis B virus reactivation

Objective To analyze the efficacy in Lamivudine for preventing nasopharyngeal carcinoma-treated-related hepatitis B virus reactivation.Methods During the time from march 2008 to March 2009,Fifty-one patients with HBV were randomly divided into two groups.One group consisted with 26 patients who received prophylactic lamivudine prior to therapy and until 8 weeks after discontinuing concurrent chemoradiotherapy or chemotherapy.The other comprised 25 patients who did not undergo prophylactic lamivudine before ...